Yuhan Corp reports that it made three poster presentations at the virtual meeting of the American Society of Clinical Oncology (ASC) centering on the positive results of Lazertinib. Its investigational anticancer drug has evidencing efficacy and safety against lung cancer based on the result of their latest multiple clinical trials.
The Poster Presentations
The company presented on positive progress with its targeted therapy for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation including Lazertinib’s therapeutic effect on 1) lung cancer, 2) brain metastasis, and 3) findings on clinical genetics on the mechanisms of resistance after the drug administration.
Also known as YH25448, it is an oral, highly potent, mutant-selective, and irreversible EGFR Tyrosine-kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type EGFR.
Clinical Investigator’s Position
Kim Sang-we, lead author of the entire study as well as a professor at the Oncology Department of Asan Medical Center, disclosed, “This study showed that Lazertinib could help treat lung cancer with ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).